Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Velcade bortezomib regulatory update

The U.K.'s National Institute for Health and Clinical Excellence (NICE) recommended the use of Velcade bortezomib to treat progressive multiple myeloma (MM), in patients who are at

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE